SIR-orexins (hypocretins) are recently discovered neuropeptides produced almost exclusively in the lateral hypothalamus. Acute administration of orexin A or B to rodents increases food intake, locomotion, grooming and face washing suggesting an involvement in arousal. 1 Recently, anatomical connections of orexin-producing cells with dopamine-containing cells in the ventral tegmental area have been documented suggesting interactions between the dopaminergic and orexinergic system. 2 This idea is corroborated by a study showing increased c-fos expression of orexin neurons induced by antipsychotic drugs (APD) in rats. 2 This was found for antidopaminergic APDs that have a high liability to induce weight gain (chlorpromazine, clozapine, olanzapine and risperdone). In contrast, the APD haloperidol that does not affect weight consistently, 3 had no effect on c-fos expression in orexin neurons. To investigate whether and how antipsychotic drugs affect orexin production in humans, we studied cerebrospinal fluid (CSF) levels of orexin A in patients suffering from schizophrenia according to DSM-IV treated in a nonrandomized fashion either with the classic APD haloperidol (n ¼ 7) or one of the atypical compounds clozapine or olanzapine (n ¼ 8) and compared these two groups to untreated patients (n ¼ 12). Subjects received a diagnostic lumbar puncture in sitting position between 8 and 10 am after informed consent was obtained. Orexin A levels were determined by a radioimmunoassay (RIA, Phoenix Pharmaceuticals, Mountain View, CA, USA). 5 Analysis of variance revealed a significant difference in CSF orexin A levels between the three groups investigated. Posthoc testing showed that mean orexin A levels in patients treated with haloperidol were significantly lower than in the untreated patients. Mean CSF orexin A levels in patients on atypical APDs were inbetween (see Figure 1 ). There were no significant differences between treatment groups with respect to age, gender, height, weight, BMI and duration of antipsychotic treatment (see Table 1 ). Also, no significant correlations were found between CSF orexin A levels and CSF storage time, the BMI of the patients or the time of APD treatment prior to lumbar puncture (data not shown).
The influence of APDs on CSF orexin levels has not been investigated so far, but Fadel et al 2 found increased c-fos expression of orexin neurons following treatment with the APDs clozapine, olanzapine, risperidone or chlorpromazine in rats. Haloperidol and other classic APDs had no effect in this study. Fadel et al 2 hypothesized that increased c-fos expression might indicate increased orexin contributing to weight gain induced by atypical APDs. This idea is not supported by our results, since clozapine and olanzapine did not affect CSF orexin levels consistently. Moreover, decreased rather than increased orexin production seems to be linked to obesity in human narcolepsy [4] [5] [6] and in orexin transgenic animals.
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The mechanisms underlying the effect of haloperidol on orexin production are unknown. Recently, important interactions between dopaminergic neurotransmission and the orexin system have been discovered. 2 Orexin-induced hyperlocomotion is mediated by the dopaminergic system of the ventral tegmental area and can be blocked by haloperidol. 7 Moreover, orexin A suppresses prolactin release at least in part through dopaminergic pathways. 8 dopaminergic transmission on orexin production, have not been observed so far. The present study suggests that dopamine might activate orexin production, while dopamine receptor blockade, in particular D2 receptor blockade, might have the opposite effect. Hence, dopamine and orexins might synergistically be involved in the promotion of wakefulness and arousal fitting recent ideas about peptidergic and neurotransmitter control of sleep and wakefulness.
Reverse interactions, that is, effects of altered
The almost complete absence of orexins in human narcolepsy 4, 5 is accompanied, among other symptoms, by severe hypersomnolence and overweight. Hence, reduced orexin levels in haloperidol-treated patients might somehow be involved in sedating and non-REM sleep-promoting effects of this drug. 9 This idea is in line with a recent study of Nishino et al 10 reporting a positive correlation between orexin A levels and sleep onset latency in untreated patients suffering from schizophrenia, suggesting that decreased orexin A production might be associated with increased sleep pressure. In the same study orexin levels in the patients did not differ from healthy controls, rendering a direct involvement of orexins in the pathophysiology of schizophrenia unlikely.
To conclude, the present results provide for the first time evidence that treatment with APDs lowers orexin production in humans. Hence, the orexin system is a novel candidate for mediating APDs' behavioral effects and might be an interesting target for novel pharmacological treatments in schizophrenia and other psychiatric disorders. 
